Surmodics (NASDAQ:SRDX - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.36) by $0.43, Zacks reports. Surmodics had a net margin of 3.99% and a return on equity of 8.06%. The company had revenue of $31.96 million during the quarter, compared to the consensus estimate of $28.79 million. During the same period in the previous year, the firm posted ($0.40) EPS. Surmodics updated its FY 2024 guidance to -0.670--0.470 EPS.
Surmodics Trading Up 3.7 %
Surmodics stock traded up $1.22 during mid-day trading on Thursday, hitting $34.55. The company's stock had a trading volume of 368,428 shares, compared to its average volume of 63,706. The company has a debt-to-equity ratio of 0.24, a current ratio of 4.84 and a quick ratio of 3.97. The stock has a market cap of $491.99 million, a price-to-earnings ratio of 92.27 and a beta of 1.04. The business has a 50 day moving average price of $28.58 and a 200-day moving average price of $31.63. Surmodics has a 12 month low of $16.79 and a 12 month high of $39.41.
Wall Street Analyst Weigh In
A number of analysts have recently issued reports on the stock. StockNews.com downgraded shares of Surmodics from a "strong-buy" rating to a "buy" rating in a report on Wednesday, April 24th. Needham & Company LLC dropped their price objective on shares of Surmodics from $47.00 to $43.00 and set a "buy" rating for the company in a report on Wednesday. Finally, Barrington Research reaffirmed an "outperform" rating and set a $71.00 price objective on shares of Surmodics in a report on Thursday.
Read Our Latest Stock Analysis on Surmodics
About Surmodics
(
Get Free Report)
Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).
Recommended Stories
Before you consider Surmodics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Surmodics wasn't on the list.
While Surmodics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.
Get This Free Report
